PL3307322T3 - Humanizowane przeciwciała anty-cd40 i ich zastosowania - Google Patents
Humanizowane przeciwciała anty-cd40 i ich zastosowaniaInfo
- Publication number
- PL3307322T3 PL3307322T3 PL16843066T PL16843066T PL3307322T3 PL 3307322 T3 PL3307322 T3 PL 3307322T3 PL 16843066 T PL16843066 T PL 16843066T PL 16843066 T PL16843066 T PL 16843066T PL 3307322 T3 PL3307322 T3 PL 3307322T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- applications
- humanized anti
- humanized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214411P | 2015-09-04 | 2015-09-04 | |
| EP16843066.8A EP3307322B1 (en) | 2015-09-04 | 2016-09-02 | Humanized anti-cd40 antibodies and uses thereof |
| PCT/US2016/050114 WO2017040932A1 (en) | 2015-09-04 | 2016-09-02 | Humanized anti-cd40 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3307322T3 true PL3307322T3 (pl) | 2021-07-05 |
Family
ID=58188471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16843066T PL3307322T3 (pl) | 2015-09-04 | 2016-09-02 | Humanizowane przeciwciała anty-cd40 i ich zastosowania |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9974855B2 (pl) |
| EP (2) | EP3906943A1 (pl) |
| JP (3) | JP6976931B2 (pl) |
| KR (2) | KR20250007054A (pl) |
| CN (2) | CN109069621B (pl) |
| AU (2) | AU2016315873B2 (pl) |
| BR (1) | BR112018004296B1 (pl) |
| CA (1) | CA3002789A1 (pl) |
| DK (1) | DK3307322T3 (pl) |
| ES (1) | ES2887602T3 (pl) |
| HU (1) | HUE056769T2 (pl) |
| MX (2) | MX2018002708A (pl) |
| PL (1) | PL3307322T3 (pl) |
| PT (1) | PT3307322T (pl) |
| SI (1) | SI3307322T1 (pl) |
| WO (1) | WO2017040932A1 (pl) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3556774B1 (en) | 2011-03-11 | 2024-01-03 | Beth Israel Deaconess Medical Center Inc. | Anti-cd40 antibodies and uses thereof |
| CN113699116A (zh) | 2014-12-10 | 2021-11-26 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| KR20250007054A (ko) | 2015-09-04 | 2025-01-13 | 프리마토프 테라퓨틱스 인크. | 인간화 항-cd40 항체 및 그의 용도 |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| WO2018115003A2 (en) | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
| AU2018278051A1 (en) | 2017-06-01 | 2020-01-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
| KR20200141986A (ko) | 2018-02-12 | 2020-12-21 | 다이어비티스-프리, 인크. | 개선된 길항성 항-인간 cd40 단클론 항체 |
| KR102728939B1 (ko) | 2018-07-20 | 2024-11-11 | 유큐(베이징) 바이오파마 코., 엘티디 | 항-cd40 항체 및 그의 용도 |
| WO2020108621A1 (zh) | 2018-11-30 | 2020-06-04 | 江苏恒瑞医药股份有限公司 | 一种cd40抗体药物组合物及其用途 |
| BR112021009835A2 (pt) | 2018-11-30 | 2021-08-17 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos |
| WO2020154627A1 (en) | 2019-01-25 | 2020-07-30 | Promab Biotechnologies, Inc. | Epcam antibody and epcam-car-t cells |
| CN113728008B (zh) * | 2019-04-10 | 2024-04-09 | 南开大学 | 抗cd40抗体及其用途 |
| BR112021021923A2 (pt) * | 2019-05-08 | 2022-02-22 | Novartis Ag | Anticorpos anti-cd40 para uso no tratamento de dm1 e insulite |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| WO2020253722A1 (en) * | 2019-06-17 | 2020-12-24 | Eucure (Beijing) Biopharma Co., Ltd | Anti-cd40 antibodies and uses thereof |
| KR20220062036A (ko) * | 2019-09-11 | 2022-05-13 | 노파르티스 아게 | 환자에서 인간 바이러스 연관된 장애를 방지하는 방법 |
| WO2021213245A1 (zh) * | 2020-04-20 | 2021-10-28 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段、其制备方法及医药用途 |
| KR20230010725A (ko) * | 2020-05-18 | 2023-01-19 | 브리스톨-마이어스 스큅 컴퍼니 | 개선된 약동학적 특성을 갖는 항체 변이체 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN115768477A (zh) * | 2021-06-29 | 2023-03-07 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
| WO2023284714A1 (zh) * | 2021-07-14 | 2023-01-19 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
| JP7732841B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732839B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732842B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732840B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732843B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| CA3237146A1 (en) * | 2021-11-05 | 2023-05-11 | John F. Paolini | Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof |
| US12234294B2 (en) * | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| KR20240095255A (ko) * | 2021-11-05 | 2024-06-25 | 키닉사 파마슈티컬스, 게엠베하 | 인간화 항-cd40 항체의 약학적 조성물 |
| CA3242941A1 (en) * | 2022-01-10 | 2023-07-13 | Kiniksa Pharmaceuticals, Gmbh | METHODS FOR TREATMENT OR REDUCING THE RISK OF GRAFT REJECTION |
| WO2024107752A2 (en) | 2022-11-15 | 2024-05-23 | Onestone Therapeutics Llc | Compositions and methods for immunomodulatory bifunctional fusion molecules |
| WO2025045766A1 (en) | 2023-08-25 | 2025-03-06 | Kiniksa Pharmaceuticals, Gmbh | Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same |
| US20260022185A1 (en) | 2024-01-03 | 2026-01-22 | Kiniksa Pharmaceuticals, Gmbh | Method of reducing aggregation in the virus-inactivated preparation of anti-cd40 antibodies |
| WO2025169146A1 (en) | 2024-02-09 | 2025-08-14 | Kiniksa Pharmaceuticals, Gmbh | Cd40 antagonist or cd154 antagonist for use in mitigating immune responses in protein and gene therapies |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
Family Cites Families (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3737433A (en) | 1964-09-05 | 1973-06-05 | Albert Ag Chem Werke | Certain oxoalkyldimethylxanthines |
| DE2819094A1 (de) | 1977-05-10 | 1978-11-23 | Sandoz Ag | Cyclosporin-derivate, ihre verwendung und herstellung |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| FI65914C (fi) | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
| EP0056782B1 (en) | 1981-01-09 | 1984-08-01 | Sandoz Ag | Novel cyclosporins |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4576284A (en) | 1983-12-02 | 1986-03-18 | Warner-Lambert Company | Closing of filled capsules |
| US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| CH667274A5 (de) | 1984-03-23 | 1988-09-30 | Sandoz Ag | Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8611905D0 (en) | 1986-05-15 | 1986-06-25 | Lilly Industries Ltd | Capsules |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8729153D0 (en) | 1987-12-14 | 1988-01-27 | Efamol Ltd | Fatty acid compositions |
| EP0327280B1 (en) | 1988-01-29 | 1992-03-18 | Sankyo Company Limited | Cyclosporin compositions |
| HU201567B (en) | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3919982A1 (de) | 1989-06-19 | 1990-12-20 | Liedtke Pharmed Gmbh | Orale lipidarzneiform |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| JPH04230389A (ja) | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
| US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US5120725A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5164495A (en) | 1991-09-18 | 1992-11-17 | Abbott Laboratories | Method for preparing a dicarboxylic acid half-acid ester of FK506 |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5234140A (en) | 1992-07-28 | 1993-08-10 | S. C. Johnson & Son, Inc. | Re-useable aerosol container |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| DK0656789T3 (da) | 1992-08-21 | 1998-08-24 | Genentech Inc | Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse. |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| FI961285L (fi) | 1993-10-01 | 1996-03-20 | Immunex Corp | CD40:n vasta-aineita |
| EP0729471A1 (en) | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US6096716A (en) | 1994-12-12 | 2000-08-01 | The Board Of Regents, The University Of Texas System | Liposome-mediated transfection of central nervous system cells |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5827822A (en) | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
| US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US20030099642A1 (en) | 1996-04-22 | 2003-05-29 | Michael J. Yellin | Therapeutic applications for the anti-t-bam (cd40l) monoclonal antibody 5c8 in the treatment of vasculitis |
| WO1997022256A1 (en) | 1995-12-19 | 1997-06-26 | National Jewish Center For Immunology And Respiratory Medicine | Method to regulate cd40 signaling |
| AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| ATE265220T1 (de) | 1998-02-04 | 2004-05-15 | Gen Hospital Corp | Kostimulatorische blockade und gemischter chimerismus in allotransplantationen |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| ATE464907T1 (de) | 1999-02-17 | 2010-05-15 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| CN100490895C (zh) | 2000-02-01 | 2009-05-27 | 泛遗传学公司 | 结合cd40的apc激活分子 |
| EP1274455A1 (en) | 2000-04-19 | 2003-01-15 | Tanox, Inc. | Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| DK2336187T3 (en) | 2000-06-19 | 2016-08-22 | Beth Israel Deaconess Medical Ct Inc | Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations |
| JP4202127B2 (ja) | 2000-10-02 | 2008-12-24 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 |
| CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20040126829A1 (en) | 2001-12-18 | 2004-07-01 | Hildebrand William H. | Anti-HLA assay and methods |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| SG148143A1 (en) | 2003-11-04 | 2008-12-31 | Novartis Vaccines & Diagnostic | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| DK1684805T3 (da) | 2003-11-04 | 2010-10-04 | Novartis Vaccines & Diagnostic | Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma |
| EP2243491A1 (en) | 2003-11-04 | 2010-10-27 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia |
| EP2236172A1 (en) | 2003-11-04 | 2010-10-06 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| ES2397631T3 (es) | 2003-12-25 | 2013-03-08 | Kyowa Hakko Kirin Co., Ltd. | Mutante antagonista de anticuerpos ANTI-CD40 |
| NZ548821A (en) | 2004-02-06 | 2009-12-24 | Univ Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EP1776105A2 (en) | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
| KR100958505B1 (ko) | 2004-07-18 | 2010-05-17 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제 |
| WO2006033386A1 (ja) | 2004-09-22 | 2006-03-30 | Kirin Beer Kabushiki Kaisha | 安定化されたヒトIgG4抗体 |
| SI1851315T1 (sl) | 2005-02-02 | 2014-06-30 | University Of Massachusetts | Humana protitelesa proti steklini in njihova uporaba |
| US20060280738A1 (en) | 2005-06-08 | 2006-12-14 | Tedder Thomas F | Anti-CD19 antibody therapy for transplantation |
| CA2609269C (en) | 2005-05-26 | 2014-08-05 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
| KR20080073725A (ko) | 2005-11-01 | 2008-08-11 | 노파르티스 아게 | 항-ｃｄ40 항체의 용도 |
| CN101351478A (zh) | 2005-11-01 | 2009-01-21 | 诺华有限公司 | 抗cd40抗体的应用 |
| BRPI0619586A2 (pt) * | 2005-12-09 | 2018-08-28 | Seattle Genetics Inc | método para o tratamento ou prevenção de um distúrbio associado com cd40 |
| US8945564B2 (en) | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| US8138134B2 (en) | 2006-09-29 | 2012-03-20 | Union Carbide Chemicals & Plastics Technology Llc | Quaternized cellulose ethers for personal care products |
| EP2125894B1 (en) | 2007-03-22 | 2018-12-19 | Biogen MA Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| RU2491095C2 (ru) | 2007-11-09 | 2013-08-27 | Новартис Аг | Применения анти-cd40-антител |
| WO2009094391A1 (en) | 2008-01-23 | 2009-07-30 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| ES2650267T3 (es) | 2008-12-05 | 2018-01-17 | Als Therapy Development Institute | Método para el tratamiento de enfermedades neurodegenerativas |
| US9562104B2 (en) | 2009-03-10 | 2017-02-07 | Baylor Research Institute | Anti-CD40 antibodies |
| PT3178851T (pt) * | 2010-03-31 | 2020-07-17 | Boehringer Ingelheim Int | Anticorpos anti-cd40 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012111762A1 (ja) | 2011-02-17 | 2012-08-23 | 協和発酵キリン株式会社 | 抗ｃｄ４０抗体の高濃度製剤 |
| EP3556774B1 (en) | 2011-03-11 | 2024-01-03 | Beth Israel Deaconess Medical Center Inc. | Anti-cd40 antibodies and uses thereof |
| AR086360A1 (es) | 2011-04-21 | 2013-12-11 | Bristol Myers Squibb Co | Polipeptidos anticuerpos que antagonizan cd40 |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| WO2014121099A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Agonist fusion protein for cd40 ox40 and uses thereof |
| JP6426693B2 (ja) | 2013-03-15 | 2018-11-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| GB201501613D0 (en) | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| WO2016199146A1 (en) | 2015-06-09 | 2016-12-15 | B. G. Negev Technologies And Applications Ltd | A controlled release system for pulmonary delivery of surfactant protein d |
| CN107771184B (zh) | 2015-06-29 | 2022-11-01 | 百时美施贵宝公司 | 针对cd40的抗体 |
| KR20250007054A (ko) | 2015-09-04 | 2025-01-13 | 프리마토프 테라퓨틱스 인크. | 인간화 항-cd40 항체 및 그의 용도 |
| WO2020078454A1 (en) | 2018-10-18 | 2020-04-23 | Sinomab Bioscience Limited | Method of modulating autoimmunity by disrupting cis‐ligand binding of siglec type antigens |
| JP2023542678A (ja) | 2020-09-21 | 2023-10-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症状態の処置のための抗ｃｄ４０抗体の使用。 |
| CN118234749A (zh) | 2021-09-17 | 2024-06-21 | 诺华股份有限公司 | 用于预防异种移植中的移植物排斥的方法 |
| CA3237146A1 (en) | 2021-11-05 | 2023-05-11 | John F. Paolini | Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof |
| WO2023081831A2 (en) | 2021-11-05 | 2023-05-11 | Diabetes-Free, Inc. | Methods and compositions for immune tolerance to aav antigens and transgene products in gene therapy |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| KR20240095255A (ko) | 2021-11-05 | 2024-06-25 | 키닉사 파마슈티컬스, 게엠베하 | 인간화 항-cd40 항체의 약학적 조성물 |
| CA3242941A1 (en) | 2022-01-10 | 2023-07-13 | Kiniksa Pharmaceuticals, Gmbh | METHODS FOR TREATMENT OR REDUCING THE RISK OF GRAFT REJECTION |
| WO2025045766A1 (en) | 2023-08-25 | 2025-03-06 | Kiniksa Pharmaceuticals, Gmbh | Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same |
| WO2025169146A1 (en) | 2024-02-09 | 2025-08-14 | Kiniksa Pharmaceuticals, Gmbh | Cd40 antagonist or cd154 antagonist for use in mitigating immune responses in protein and gene therapies |
-
2016
- 2016-09-02 KR KR1020247043041A patent/KR20250007054A/ko active Pending
- 2016-09-02 EP EP21156562.7A patent/EP3906943A1/en active Pending
- 2016-09-02 DK DK16843066.8T patent/DK3307322T3/da active
- 2016-09-02 KR KR1020187009524A patent/KR102779818B1/ko active Active
- 2016-09-02 HU HUE16843066A patent/HUE056769T2/hu unknown
- 2016-09-02 WO PCT/US2016/050114 patent/WO2017040932A1/en not_active Ceased
- 2016-09-02 MX MX2018002708A patent/MX2018002708A/es unknown
- 2016-09-02 PL PL16843066T patent/PL3307322T3/pl unknown
- 2016-09-02 BR BR112018004296A patent/BR112018004296B1/pt active IP Right Grant
- 2016-09-02 PT PT168430668T patent/PT3307322T/pt unknown
- 2016-09-02 CN CN201680064574.2A patent/CN109069621B/zh active Active
- 2016-09-02 CA CA3002789A patent/CA3002789A1/en active Pending
- 2016-09-02 ES ES16843066T patent/ES2887602T3/es active Active
- 2016-09-02 SI SI201631164T patent/SI3307322T1/sl unknown
- 2016-09-02 CN CN202211072946.XA patent/CN116063481A/zh active Pending
- 2016-09-02 JP JP2018512313A patent/JP6976931B2/ja active Active
- 2016-09-02 AU AU2016315873A patent/AU2016315873B2/en active Active
- 2016-09-02 EP EP16843066.8A patent/EP3307322B1/en active Active
-
2017
- 2017-12-01 US US15/829,352 patent/US9974855B2/en active Active
-
2018
- 2018-03-02 MX MX2022015631A patent/MX2022015631A/es unknown
- 2018-04-17 US US15/955,393 patent/US10201608B2/en active Active
- 2018-12-27 US US16/234,110 patent/US10772958B2/en active Active
-
2020
- 2020-08-14 US US16/994,249 patent/US11439706B2/en active Active
-
2021
- 2021-07-20 JP JP2021119613A patent/JP7763612B2/ja active Active
-
2022
- 2022-08-08 US US17/818,188 patent/US12514924B2/en active Active
- 2022-10-04 AU AU2022241635A patent/AU2022241635A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023084151A patent/JP2023103460A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3307322T3 (pl) | Humanizowane przeciwciała anty-cd40 i ich zastosowania | |
| PL3274370T3 (pl) | Przeciwciała anty-ceacam6 i ich zastosowania | |
| DK3303395T3 (da) | Anti-cd40-antistoffer og anvendelser deraf | |
| PL3383916T3 (pl) | Przeciwciała anty-cd73 i ich zastosowania | |
| PL3295951T3 (pl) | Przeciwciała anty-pvrig i sposoby ich zastosowania | |
| PL3280441T3 (pl) | Przeciwciała przeciwko sortilinie i sposoby ich stosowania | |
| CL2018000370A1 (es) | Nuevos anticuerpos anti-pd-1 | |
| IL255949A (en) | Antibodies against ox40 and uses thereof | |
| EP3426686C0 (en) | Humanized Anti-PACAP Antibodies and Their Uses | |
| HUE051700T2 (hu) | Anti-PD-1 antitestek | |
| IL259713A (en) | Anti-dr5 antibodies and methods of use thereof | |
| DK3368572T3 (da) | Anti-pd-1-antistoffer og -sammensætninger | |
| DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
| DK3332006T3 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
| PL3148579T3 (pl) | Przeciwciała anty-gitr i sposoby ich zastosowania | |
| PL4234581T3 (pl) | Przeciwciała terapeutyczne i ich zastosowania | |
| KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| PL3280440T3 (pl) | Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania | |
| HUE056670T2 (hu) | Anti-CD40 antitestek és alkalmazásaik | |
| EP3835319C0 (en) | Humanized Anti-ACTH Antibodies and Their Use | |
| DK3452513T3 (da) | Humaniserede anti-il-ir3-antistoffer | |
| IL248402B (en) | Humanized antibodies against ceacam1 | |
| PL3359563T3 (pl) | Receptory antygenów i ich zastosowania | |
| DK3368567T3 (da) | Humaniseret anti-dkk2-antistof og anvendelser heraf |